Common Contracts
4 similar Consulting Agreement contracts by Merrimack Pharmaceuticals Inc
TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENTConsulting Agreement • July 17th, 2019 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
This Transition, Separation and Release of Claims Agreement (the “Agreement”) is being provided to Daryl C. Drummond (“Executive”) on June 14, 2019 (the “Receipt Date”) and is made as of the Agreement Effective Date (as defined below) by and between Executive and Merrimack Pharmaceuticals, Inc. (the “Company”) (together, the “Parties”).
TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENTConsulting Agreement • July 17th, 2019 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
This Transition, Separation and Release of Claims Agreement (the “Agreement”) is being provided to Jeffrey A. Munsie (“Executive”) on June 14, 2019 (the “Receipt Date”) and is made as of the Agreement Effective Date (as defined below) by and between Executive and Merrimack Pharmaceuticals, Inc. (the “Company”) (together, the “Parties”).
TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENTConsulting Agreement • July 17th, 2019 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
This Transition, Separation and Release of Claims Agreement (the “Agreement”) is being provided to Richard Peters (“Executive”) on June 14, 2019 (the “Receipt Date”) and is made as of the Agreement Effective Date (as defined below) by and between Executive and Merrimack Pharmaceuticals, Inc. (the “Company”) (together, the “Parties”).
TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENTConsulting Agreement • July 17th, 2019 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
This Transition, Separation and Release of Claims Agreement (the “Agreement”) is being provided to Jean M. Franchi (“Executive”) on June 14, 2019 (the “Receipt Date”) and is made as of the Agreement Effective Date (as defined below) by and between Executive and Merrimack Pharmaceuticals, Inc. (the “Company”) (together, the “Parties”).
